AT166471B - - Google Patents
Info
- Publication number
- AT166471B AT166471B AT166471DA AT166471B AT 166471 B AT166471 B AT 166471B AT 166471D A AT166471D A AT 166471DA AT 166471 B AT166471 B AT 166471B
- Authority
- AT
- Austria
- Prior art keywords
- strophanthin
- levulose
- solution
- pure
- solutions
- Prior art date
Links
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 229960002737 Fructose Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- -1 B. strophanthin Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung injizierbarer Lösungen von k-Strophanthin
Es sind Injektionslösungen bekannt, welche Glycoside, z. B. Strophanthin, in Glucose-bzw.
Invertzuckerlösungen gelöst enthalten.
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung injizierbarer Lösungen von k-Strophanthin, welches im wesentlichen darin besteht, dass als Lösungs-und Stabüisierungsmittel für das k-Strophantin eine Lösung von reiner Lävulose verwendet und die das Strophanthin enthaltende Lävuloselösung in an sich bekannter Weise kurze Zeit auf mindestens 60-70 0 C erwärmt wird.
Reine Lävulose wirkt, wie sich gezeigt hat, auf das chemisch labile k-Strophanthin stabilisierend.
Da Lävulose im Gegensatz zu Glucose schon in der Kälte kräftig reduziert, wirkt es oxydierenden Einflüssen entgegen. Man erhält in der oben angegebenen Weise haltbare, in ihrer Wirksamkeit völlig stabile k-Strophanthinlösungen, die auch bei langer Lagerung ihre Wirksamkeit durch oxydative Einflüsse oder durch hydrolytische Spaltung des k-Stophanthins nicht verlieren. Es treten weder Fällungen des k-Strophanthins ein, noch Wirksamkeitsveränderungen, was auf die Bildung von Additionsverbindungen und einen Austausch des Zuckermoleküles zurückgeführt werden kann. Die therapeutische Wirkung der erfindunggemäss hergestellten Präparate ist ausgezeichnet.
Beispiel : 990 cm3 21 %ige Lävuloselösung werden mit 10 cm3 einer 25 mg enthaltenden k-Strophanthinlösung versetzt, durch Filter entkeimt, in Ampullen zu 10 cm3 gefüllt, zugeschmolzen und mehrmals 15 Minuten auf 1001 C erwärmt (tyndallisiert).
**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.
<Desc / Clms Page number 1>
Process for the preparation of injectable solutions of k-strophanthin
Injection solutions are known which contain glycosides, e.g. B. strophanthin, in glucose or.
Contains dissolved invert sugar solutions.
The present invention relates to a process for the production of injectable solutions of k-strophanthin, which essentially consists in using a solution of pure levulose as the solvent and stabilizing agent for the k-strophanthin and short the strophanthin-containing levulose solution in a known manner Time to at least 60-70 0 C is heated.
As has been shown, pure levulose has a stabilizing effect on the chemically labile k-strophanthin.
Since levulose, in contrast to glucose, is already strongly reduced in the cold, it counteracts oxidizing influences. In the manner indicated above, durable k-strophanthin solutions which are completely stable in their effectiveness and which do not lose their effectiveness due to oxidative influences or hydrolytic cleavage of the k-stophanthin even after long storage are obtained. There is neither precipitation of k-strophanthin nor changes in effectiveness, which can be attributed to the formation of addition compounds and an exchange of the sugar molecule. The therapeutic effect of the preparations produced according to the invention is excellent.
Example: 990 cm3 of 21% levulose solution are mixed with 10 cm3 of a k-strophanthin solution containing 25 mg, sterilized through a filter, filled into ampoules of 10 cm3, melted and heated several times for 15 minutes to 1001 ° C. (cylindricalized).
** WARNING ** End of DESC field may overlap beginning of CLMS **.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
AT166471B true AT166471B (en) |
Family
ID=3298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT166471D AT166471B (en) |
Country Status (1)
Country | Link |
---|---|
AT (1) | AT166471B (en) |
-
0
- AT AT166471D patent/AT166471B/de active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69500806T2 (en) | SPORTS DRINK | |
DE2240782A1 (en) | METHOD FOR PRODUCING AN IRON SACCHARIDE COMPLEX | |
DE2417859C2 (en) | Process for the preparation of simple or mixed heparin salts and medicaments containing them | |
DE2002385C3 (en) | Process for the production of lactulose concentrate | |
AT166471B (en) | ||
DE3641188A1 (en) | ALCOHOLIC BEVERAGE AND METHOD FOR PRODUCING THE SAME | |
DE1212679B (en) | Process for the preparation of insulin solutions | |
DE19633393C1 (en) | Saffron spirit | |
DE3019895C2 (en) | ||
DE2904029B2 (en) | Process for making sugar-free chewing gum | |
DE3530790A1 (en) | Method for obtaining stable camomile extracts rich in active substance | |
CH241111A (en) | Process for the production of an easily soluble, durable product containing calcium and the gluconic acid residue. | |
DE1282430C2 (en) | PROCESS FOR THE PRODUCTION OF A FAT MIXTURE CONTAINING COCOA BUTTER WITH A LOW MELTING TEMPERATURE RANGE | |
AT393454B (en) | EYE DROP ADDITION | |
DE3113035C2 (en) | ||
DE288338C (en) | ||
AT149124B (en) | Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. | |
DE752680C (en) | Anion exchange | |
CH637826A5 (en) | Intravenous, aqueous SULFONAMIDLOESUNG AND METHOD FOR PRODUCING. | |
DE1182776B (en) | Process for increasing the solubility of theophylline | |
AT162644B (en) | Process for the production of durable, supersaturated solutions of saccharide derivatives of the adrenal cortex hormone series | |
AT166052B (en) | ||
DE884857C (en) | Process for the production of durable, saturated solutions of saccharide derivatives of the adrenal cortex hormone series | |
DE662835C (en) | Process for the preparation of water-soluble laxatives | |
AT228936B (en) |